Stocks and Investing Stocks and Investing
Thu, November 28, 2024
[ 09:01 AM ] - United States, Thomas Matters
Is Pfizer Stock in Trouble?

Embecta upgraded to Buy from Neutral at BTIG


Published on 2024-11-28 02:40:57 - Thomas Matters, WOPRAI
  Print publication without navigation

  • BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded

Embecta, a medical device company focused on diabetes care, was upgraded to a "Buy" rating from "Neutral" by BTIG analyst Marie Thibault. This upgrade was based on the company's strong performance in its core business, particularly in the U.S. where it holds a significant market share in insulin syringes and pen needles. The analyst highlighted that despite potential challenges like the loss of exclusivity for some products, Embecta's strategic initiatives, including new product launches and international expansion, are expected to drive growth. Additionally, the company's efforts to manage costs and improve operational efficiency were noted as positive factors contributing to the optimistic outlook. The price target set by BTIG for Embecta's stock reflects confidence in its future profitability and market position.

Read the Full Business Insider Article at [ https://markets.businessinsider.com/news/stocks/embecta-upgraded-to-buy-from-neutral-at-btig-1034071393 ]

Contributing Sources